Sunshine Anjin successfully secured over 100 million yuan in Pre-A round financing led by Qiming Venture Partners to advance its innovative pain treatment drug targeting Nav1.8.

Target Company Overview

Sunshine Anjin (Nanjing) Biopharmaceutical Technology Co., Ltd. (hereafter referred to as "Sunshine Anjin") is an innovative enterprise focused on the development of novel pain treatment drugs. The company recently announced the successful completion of over 100 million yuan in its Pre-A round financing, led by Qiming Venture Partners. The funds will be used to advance the development of its globally competitive pain treatment research pipeline, particularly targeting the sodium ion channel Nav1.8 with small molecule drugs.

Founded by Professor Lei Xiaoguang from Peking University and clinical physician Professor Yang Yong from the Chinese Academy of Medical Sciences’ Dermatology Hospital, Sunshine Anjin has cultivated a research team with rich experience in innovative drug development and international competitiveness. The company specializes in the research of new analgesic drugs targeting the Nav1.8 and Nav1.7 sodium ion channels that are highly associated with the body's perception of pain.

Industry Overview in China

The prevalence of chronic pain worldwide remains alarmingly high, with approximately one in five people experiencing chronic pain, according to the International Association for the Study of Pain. In China, more than 300 million individuals are reported to be suffering from chron